OS Therapies files Form D for debt offering worth up to $9.25 million

OS Therapies Inc, based in Grasonville, Maryland, filed a Form D notice with the Securities and Exchange Commission dated July 15, 2026, disclosing a new offering of exempt securities. The company is incorporated in Delaware and was formed over five years ago.¹

The filing claims an exemption under Rule 506(b) of Regulation D.¹ The securities offered include debt as well as an option, warrant or other right to acquire another security, and a security to be acquired upon exercise of such a right.¹ The company indicated that the offering is not connected to a merger, acquisition, or exchange offer.

The total offering amount listed is $9,250,000, with $1,600,000 already sold and $7,650,000 remaining to be sold.¹ The date of first sale was listed as June 30, 2026.¹ The company does not intend the offering to last more than one year.¹

The filing reports a total of one investor who has already invested in the offering.¹ The minimum investment accepted from any outside investor is listed as $0.¹ No sales commissions or finders' fees were reported.¹ The amount designated for payments to executive officers, directors, or promoters from the offering proceeds was listed as $0.¹

Related persons named in the filing include Paul A. Romness, listed as Chairman, President and Chief Executive Officer, and Robert G. Petit, listed as Chief Medical Officer and Chief Scientific Officer.¹ Christopher P. Acevedo, identified as Chief Financial Officer, is also listed among related persons and signed the filing on the company's behalf on July 15, 2026, according to the signature block. The issuer elected to decline disclosure of its revenue range or aggregate net asset value.¹